ArticleNature medicine2016
Reply to "Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status".
Abstract readLetterComment
In one paragraph
Article in Nature medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 10 citations in OpenAlex.
- An overview of BAP1 biological functions and current therapeutics.Biochimica et biophysica acta. Reviews on cancer · 2025Review
- A centrosome-related gene signature for predicting the overall survival of uveal melanoma.Translational cancer research · 2024Article
- Epigenetic modifiers: activities in renal cell carcinoma.Nature reviews. Urology · 2018Review
- Resetting the epigenetic balance of Polycomb and COMPASS function at enhancers for cancer therapy.Nature medicine · 2018Article
- BAP1 mutations in high-grade meningioma: implications for patient care.Neuro-oncology · 2017Review
- Epigenetics of hematopoiesis and hematological malignancies.Genes & development · 2016Review
Corrections and comments
- Comment on
- Comment on
Authors and funding
31 authors at 6 institutions in 1 country.
Lindsay M LaFaveHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Wendy BéguelinDepartment of Hematology-Oncology, Weill Cornell Medical College, New York, New York, USA.
Richard KocheThe Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Matt TeaterDepartment of Hematology-Oncology, Weill Cornell Medical College, New York, New York, USA.
Barbara SpitzerHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Alan ChramiecThe Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Efthymia PapalexiHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Matthew D KellerHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Todd HricikHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Katerina KonstantinoffHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Jean-Baptiste MicolHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Benjamin DurhamHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Sarah K KnutsonEpizyme, Inc., Cambridge, Massachusetts, USA.
John E CampbellEpizyme, Inc., Cambridge, Massachusetts, USA.
Gil BlumChemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Xinxu ShiChemical Synthesis Core, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Emma H DoudProteomics Center of Excellence, Northwestern University, Evanston, Illinois, USA.
Andrei V KrivtsovThe Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Young Rock ChungHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Inna KhodosAnti-Tumor Assessment Core, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Elisa de StanchinaAnti-Tumor Assessment Core, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Ouathek OuerfelliChemical Synthesis Core, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Prasad S AdusumilliDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Paul M ThomasProteomics Center of Excellence, Northwestern University, Evanston, Illinois, USA.
Neil L KelleherProteomics Center of Excellence, Northwestern University, Evanston, Illinois, USA.
Minkui LuoChemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Heike KeilhackEpizyme, Inc., Cambridge, Massachusetts, USA.
Omar Abdel-WahabHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Ari MelnickDepartment of Hematology-Oncology, Weill Cornell Medical College, New York, New York, USA.
Scott A ArmstrongThe Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Ross L LevineHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Memorial Sloan Kettering Cancer Center · USCornell University · USEpizyme (United States) · USNorthwestern University · USKettering University · USTri-Institutional PhD Program in Chemical Biology · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MProfile substrates and inhibitors of protein lysine methyltransferaseR01GM096056 · NIGMS · SLOAN-KETTERING INST CAN RESEARCH · PI LUO, MINKUI · 2011 to 2018
$3.2MNCI NIH HHS P30 CA008748
Abstract
PubMed holds no abstract for this paper.
Indexed as
MelanomaUveal NeoplasmsHumansTumor Suppressor ProteinsUbiquitin ThiolesteraseUveal MelanomaTumor Suppressor ProteinsUbiquitin Thiolesterase
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.